Matthew R Henn sold $22k of MCRB
See Remarks at Seres Therapeutics, Inc.. 1,257 shares at an average of $17.30, traded Nov 15, 2025, filed Nov 18, 2025.
Score components
- +15RoleOfficer
- 0Trade size$22k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -38.2%, 3m -66.5%, 6m -69.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-286226, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2025 | MOption exercise Common Stock10b5-1 | +3,998 | - | - | 8,546 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock10b5-1 | +140 | - | - | 8,686 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock10b5-1 | +98 | - | - | 8,784 | Nov 18, 2025 |
| Nov 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,257 | $17.30 | $22k | 7,527 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,998 | $0.00 | $0 | 0 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -140 | $0.00 | $0 | 704 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -98 | $0.00 | $0 | 878 | Nov 18, 2025 |
Related signals
Other insiders at Seres Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Seres Therapeutics, Inc. | Kelly Brady See Remarks | $444 59 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $595 79 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $580 77 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $661 78 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $754 89 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Eric D. Shaff CEO and President | $2,194 259 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Teresa L. Young See Remarks | $635 75 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $1,315 76 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Eric D. Shaff CEO and President | $3,754 217 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Teresa L. Young See Remarks | $18k 1,042 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.